Results 191 to 200 of about 1,425,061 (397)

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

New England Journal of Medicine, 2018
A. Grothey, A. Sobrero, A. Shields, T. Yoshino, J. Paul, J. Taieb, J. Souglakos, Q. Shi, R. Kerr, R. Labianca, J. Meyerhardt, D. Vernerey, T. Yamanaka, I. Boukovinas, J. Meyers, L. Renfro, D. Niedzwiecki, Toshiaki Watanabe, V. Torri, M. Saunders, D. Sargent, T. André, T. Iveson   +22 more
semanticscholar   +1 more source

Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: Impact on the delivery of local-regional radiation therapy

, 1999
Halle C. F. Moore, Rosemarie Mick, Lawrence J. Solin, Cheryl Sickles, Patricia Mangan, Selina M. Luger, Kevin R. Fox, Lynn M. Schuchter, Elwyn Loh, David Porter, Stephen J. Schuster, Gordon P. Buzby, Eli Glatstein, Leslie E. Silberstein, Edward A. Stadtmauer   +14 more
openalex   +1 more source

Gastric tumorigenesis after radical resection combined with adjuvant chemotherapy for colorectal cancer: two case reports and a literature review [PDF]

, 2021
Tao Li, Guoliang Liu, Jiannan Li, Jian Cui, Xinyu Wang, Wei Li, Zeyun Zhao, Kai Zhang, Tongjun Liu   +8 more
openalex   +1 more source

Colorectal Cancer Cell's Weapon: RNF32 Engages SPP1+ Macrophages to Foster Liver Metastasis, Targeted by Indole‐3‐Acetic Acid

Advanced Science, EarlyView.
Cytoplasmic RNF32 fuels CRC liver metastasis by degrading GSK3β, which stabilizes β‐catenin and activates Wnt/EMT. Moreover, RNF32 rewires the metastatic niche: it depletes CD8+/CD4+ T and NK cells while recruiting SPP1+ macrophages (which boost tumor stemness via CD44), fibroblasts, and immunosuppressive monocytes to aid colonization.
Hongyu Wang, Shipeng Dai, Yuchen Xie, Pengyu Chen, Yue Chai, Chongyu Wang, Xueying Huang, Xiao Dong, Junfeng Shi, Yongxiang Xia, Xiaofeng Qian, Weiwei Tang, Yichan Zhou   +12 more
wiley   +1 more source

Supplementary Figure Legends from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer

, 2023
Hangcheng Fu, Yu Zhu, Yiwei Wang, Zheng Liu, Junyu Zhang, Huyang Xie, Qiang Fu, Bo Dai, Dingwei Ye, Jiejie Xu   +9 more
openalex   +1 more source

PCN31 Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment for Patients with HER2-Positive EARLY Breast Cancer: Update Results after National Drug Reimbursement LIST Adjustment in China [PDF]

, 2020
Xin‐Yuan Guan, H.C. Li, Qianjun Chen, C. Hao, J.J. Li, Y.S. Wang, J. Zhang, He Xu, C. Liu, Qiaoli Yang, Aixia Ma   +10 more
openalex   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy

, 2000
Marcella Mottolese, Maria Benevolo, Girolamo Del Monte, Simonetta Buglioni, Paola Papaldo, Cecilia Nisticò, Franco Di Filippo, Stefania Vasselli, Patrizia Vici, Claudio Botti   +9 more
openalex   +2 more sources

P2-206: Clinical responses of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy [PDF]

, 2007
Hisashi Saji, Masahiro Tsuboi, Kuniharu Miyajima, Naohiro Kajiwara, Tatsuo Ohira, T Hirano, Harubumi Kato   +6 more
openalex   +1 more source

Neoadjuvant and Adjuvant Chemotherapy for Cholangiocarcinoma [PDF]

, 2022
Hee Seung Lee
openalex   +1 more source